Viking Global Investors
Viking Global Investors is an investment firm that uses fundamental analysis to select investments across industries and geographies.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Viking Global Investors Information
Geographic Data
Address: 55 Railroad Avenue
City: Greenwich
State: CT
Zip: 06830
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
1,562,596Website Global Rank
16,000Website Monthly Traffic
Twitter Followers
Description
Viking Global Investors is an investment firm that uses fundamental analysis to select investments across industries and geographies. It is a global investment firm managing more than twenty billion in capital across long-short equity and long-only strategies. The firm was established in 1999 and is headquartered in Greenwich, Connecticut, with offices in New York City, Hong Kong, and London.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2016 | Trace Genomics | Seed Round | 4M |
| 1/2021 | Affinivax | Series C | 226M |
| 11/2018 | Roivant Sciences | Private Equity Round | 0 |
| 9/2022 | RayzeBio | Series D | 160M |
| 6/2017 | Yes To | Equity | 56M |
| 6/2019 | Viela Bio | Series B | 0 |
| 7/2021 | Genomatica | Series C | 0 |
| 12/2022 | Pearl Health | Series B | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 1/2022 | Xcell Biosciences | Series B | 27.5M |
| 11/2021 | Color | Series E | 100M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 2/2018 | Boost Biomes | Seed Round | 2M |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 1/2015 | Moderna Therapeutics | Series E | 0 |
| 10/2021 | Groove | Series B | 45M |
| 6/2022 | AlphaSense | Series D | 225M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 1/2023 | Ensoma | Series B | 0 |
| 2/2016 | EpiBiome | Series A | 6M |
| 12/2022 | Vector Biomed | Venture Round | 15M |
| 4/2021 | Lightmatter | Series B | 80M |
| 5/2020 | Checkerspot | Series B | 36M |
| 6/2021 | Iterable | Series E | 0 |
| 4/2021 | Icosavax | Series B | 0 |
| 9/2015 | Impossible Foods | Series D | 108M |
| 8/2015 | Editas Medicine | Series B | 0 |
| 6/2016 | Ginkgo Bioworks | Series C | 0 |
| 3/2021 | Ecovative Design | Series D | 60M |
| 4/2021 | Atlast Food | Series A | 40M |
| 1/2023 | SetPoint Medical | Venture Round | 0 |
| 8/2020 | Kinnate Biopharma | Series C | 98M |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2020 | Athira Pharma | Series B | 85M |
| 7/2020 | VelosBio | Series B | 137M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 11/2019 | PMV Pharmaceuticals | Series C | 0 |
| 1/2022 | Cognism | Series C | 0 |
| 12/2020 | Boost Biomes | Series A | 2M |
| 11/2007 | Vivacta | Series B | 12M |
| 10/2019 | Algen Biotechnologies | Pre Seed Round | - |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 6/2017 | Deciphera Pharmaceuticals | Series C | 52M |
| 6/2019 | Druva | Series G | 0 |
| 5/2023 | Lightmatter | Series C | 0 |
| 10/2021 | Global Processing Services | Private Equity Round | 300M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 2/2020 | Polaris Genomics | Seed Round | 2M |
| 3/2019 | Astarte Medical | Series A | 0 |
| 3/2021 | Amunix | Series B | 117M |
| 3/2020 | AbCellera Biologics | Series A | 75M |
| 5/2020 | Ginkgo Bioworks | Series F | 70M |
| 5/2020 | AbCellera | Series B | 105M |
| 9/2019 | Ginkgo Bioworks | Series E | 0 |
| 11/2021 | Cloudbeds | Series D | 0 |
| 10/2020 | Dock | Private Equity Round | 170M |
| 6/2015 | Credit Karma | Series E | 175M |
| 5/2019 | Impossible Foods | Series E | 300M |
| 1/2021 | Color | Series D | 167M |
| 4/2021 | Druva | Series H | 147M |
| 7/2020 | Mantra Bio | Series A | 25M |
| 3/2018 | Joyn Bio | Series A | 0 |
| 3/2020 | Impossible Foods | Series F | 500M |
| 1/2022 | Standard BioTools | Post-IPO Equity | 0 |
| 1/2021 | Resilient Biotics | Series A | 7.2M |
| 4/2014 | Adaptive Biotechnologies | Series C | 5M |
| 8/2019 | MedAnswers | Seed Round | 5M |
| 12/2017 | Ginkgo Bioworks | Series D | 0 |
| 9/2017 | Joyn Bio | Series A | 0 |
| 10/2018 | Genomatica | Equity | 90M |
| 3/2019 | Mediphage Bioceuticals | Convertible Note | 3.5M |
| 5/2020 | Apeel Sciences | Series D | 0 |
| 2/2022 | Cazoo | Post-IPO Debt | 0 |
| 12/2021 | DermBiont | Series A | 0 |
| 7/2016 | Roivant Sciences | Private Equity Round | 500M |
| 4/2014 | Birchbox | Series B | 60M |
| 10/2016 | Biome Makers | Seed Round | 2.2M |
| 6/2021 | Motif | Series B | 0 |
| 6/2018 | Checkerspot | Seed Round | 5M |
| 7/2018 | Apeel Sciences | Series C | 70M |
| 11/2016 | Prospect Bio | Seed Round | 0 |
| 8/2019 | Motif | Series A | 27.5M |
| 8/2021 | Apeel Sciences | Series E | 0 |
| 4/2019 | NextGen Jane | Series A | 9M |
| 5/2022 | Locus Biosciences | Series B | 0 |
| 6/2023 | Ecovative Design | Series E | 30M |
| 12/2019 | Iterable | Series D | 60M |
| 10/2022 | Arctic Wolf | Convertible Note | 401M |
| 8/2021 | Biome Makers | Series B | 0 |
| 6/2019 | DermBiont | Series A | 0 |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 10/2020 | Arctic Wolf | Series E | 200M |
| 8/2017 | Auris Health | Series D | 0 |
| 10/2021 | Arcaea | Series A | 78M |
| 11/2018 | Auris Health | Series E | 0 |
| 7/2017 | Vets First Choice | Private Equity Round | 223M |
| 12/2017 | Zentalis Pharmaceuticals | Series B | 34M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 3/2021 | ID.me | Series C | 0 |
| 4/2020 | Rallybio | Series B | 0 |
| 4/2023 | ID.me | Series D | 0 |
| 9/2021 | AlphaSense | Series C | 180M |
| 4/2023 | AlphaSense | Series D | 100M |
| 10/2020 | Allonnia | Series A | 40M |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 9/2021 | Astarte Medical | Series A | 0 |
| 6/2009 | Vivacta | Venture Round | 4.5M |
| 2/2017 | Xcell Biosciences | Series A | 12M |
| 6/2021 | Clip | Series D | 250M |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 8/2021 | Algen Biotechnologies | Seed Round | - |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 1/2023 | Mantra Bio | Series A | 9M |
| 2/2020 | TruGenomix | Seed Round | 0 |
| 1/2020 | Color | Series D | 75M |
| 4/2022 | Revenova | Venture Round | 0 |
| 8/2017 | aTyr Pharma | Post-IPO Equity | 45M |
| 10/2021 | Patina | Series A | 50M |
| 4/2014 | Adaptive Biotechnologies | Series D | 100M |
| 2/2016 | Vitagene | Seed Round | 2M |
| 11/2020 | Pharvaris | Series C | 80M |
| 10/2020 | LianBio | Series A | 0 |
| 4/2019 | Checkerspot | Series A | 13M |
| 5/2019 | Inhibrx | Private Placement | 40M |
| 7/2015 | Ginkgo Bioworks | Series B | 0 |
| 11/2020 | VastBiome | Seed Round | 4.5M |
| 8/2021 | Talkdesk | Series D | 230M |
| 3/2020 | Cloudbeds | Series C | 0 |
| 7/2020 | Talkdesk | Series C | 143M |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 10/2020 | Solarea Bio | Series A | 11.2M |
| 5/2023 | Solarea Bio | Series B | 0 |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 7/2021 | Arctic Wolf | Series F | 150M |
| 8/2020 | PMV Pharmaceuticals | Series D | 70M |
| 4/2020 | Affinivax | Series B | 120M |
| 5/2022 | Dock | Private Equity Round | 0 |
| 10/2018 | Talkdesk | Series B | 100M |
| 10/2021 | Roivant Sciences | Post-IPO Equity | 0 |
| 6/2020 | HeadLight | Series B | 25.6M |
| 6/2021 | Antheia | Series B | 0 |
| 8/2021 | Pepgen | Venture Round | 0 |
| 6/2022 | AlphaSense | Series D | 0 |
| 5/2022 | Locus Biosciences | Series B | 0 |
| 5/2022 | Dock | Private Equity Round | 0 |
| 4/2022 | Revenova | Venture Round | 0 |
| 2/2022 | Cazoo | Post-IPO Debt | 0 |
| 1/2022 | Standard BioTools | Post-IPO Equity | 0 |
| 1/2022 | Xcell Biosciences | Series B | 0 |
| 1/2022 | Cognism | Series C | 0 |
| 12/2021 | DermBiont | Series A | 0 |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
